Wilson & Company Names Ryan Branfort as Chief Information Officer
ALBUQUERQUE, N.M.–(BUSINESS WIRE)–Wilson & Company, Inc., Engineers & Architects is pleased to announce that…
ISP
First AML Patient Successfully Transplanted with Vor Bio’s Investigational Trem-cel (VOR33) and Tolerated Mylotarg™
Trem-cel (formerly VOR33) successfully manufactured and engrafted normally Blood counts successfully maintained following post-transplant treatment…
ONK Therapeutics Boosts Drug Development Experience and Expands US Presence with the Appointment of Bruce McCreedy Ph.D. as Chief Scientific Officer
Bruce McCreedy Ph.D. joins the Executive Leadership Team as Chief Scientific Officer, as the company…
CRISPR Therapeutics to Present at the 2022 BMO Growth & ESG Conference
ZUG, Switzerland and BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a…
CRISPR Therapeutics to Present at the 2022 BMO Growth & ESG Conference
ZUG, Switzerland and BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a…
SparingVision’s lead asset SPVN06 clears IND application in the US for the treatment of retinitis pigmentosa
SparingVision’s lead asset SPVN06 clears IND application in the US for the treatment of retinitis…
SparingVision’s lead asset SPVN06 clears IND application in the US for the treatment of retinitis pigmentosa
SparingVision’s lead asset SPVN06 clears IND application in the US for the treatment of retinitis…
Web3 Working Group launches with $2M to drive adoption of Web3 infrastructure
Backed by Arweave,The Graph, Livepeer, and Akash, nonprofit aims to educate and drive adoption of…
Intellia Therapeutics Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage…
IMUNON Announces Strategic Investment in Transomic Technologies
Investment of $375,000 with Senior Convertible Notes and Warrants; Strengthens Development Capabilities for IMUNON’s PLACCINE…
Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial
EDIT-101 demonstrates a favorable safety profile across all dose cohorts Preliminary efficacy signals of consistent…
Intellia Therapeutics Presents New Interim Data from First-in-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the American College of Allergy, Asthma & Immunology 2022 Annual Scientific Meeting
Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested…
CRISPR Therapeutics Presents Data at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
ZUG, Switzerland and BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a…
Imugene’s onCARlytics combination with Celularity’s placental-derived off-the-shelf allogeneic CYCART-19 T cells preclinical data presented at SITC Annual Meeting
SYDNEY, Australia and FLORHAM PARK, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) — Imugene Limited (ASX:IMU),…
Inspur Information Next-Generation G7 Server Platform Offers Power and Flexibility with Support for AMD EPYC™ 9004 Series Processors
The platform achieves an 86% performance improvement, providing a greener solution with liquid cooling technology….
Cellectis Publishes Manuscript in Frontiers Bioengineering and Biotechnology Unveiling Efficient Multitool/Multiplex Gene Engineering combining TALEN® and TALE Base Editors (TALE-BE)
NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) — Cellectis (the “Company”) (Euronext Growth: ALCLS –…
Valneva Reports Nine-Month 2022 Results and Provides Corporate Updates
Total nine-month revenues of €249.9 million, a ~ 3.5-fold increase compared to 2021 Product sales…
Formal Opening of DE-CIX Richmond Internet Exchange – Bringing World-Class Connectivity Solutions to Henrico County
Formal opening ceremony attended by “Father of the Internet” Vint Cerf and Secretary of Administration…
Nkarta Presents Data Supporting Engineered NK Cell Based Combination Therapies and Next Generation Commercial-Scale Manufacturing Platform at SITC 37th Annual Meeting
Improved Anti-Tumor Activity Demonstrated by the Combination of NKX019 and a CD20-directed Monoclonal Antibody in…
Intellia Presents Updated Interim Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis at the American Heart Association Scientific Sessions 2022
Data presented in late-breaking oral presentation demonstrated deep and consistent TTR reduction following a single…